Cipher Pharma (CPHR) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St futures slip as second half of year begins with Mideast worries
- Oil falls over 1% as markets await outcome of Iran-US talks, US stocks data
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar firm at 1-year highs as Euro Inflation cools; yen in Intervention zone
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Cipher Pharma (CPHR) Launches Actikerall in Canada
February 22, 2016 7:05 AM ESTCipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced the Canadian launch of Actikerall (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients1. Actinic keratosis, also known as solar keratosis, is a skin condition caused by exposure to ultraviolet radiation2. Cipher... More
